FibroBiologics, Cash And Short Term Investments vs Net Debt Analysis
| FBLG Stock | 2.56 0.09 3.64% |
FibroBiologics, Common financial indicator trend analysis is much more than just examining FibroBiologics, Common latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroBiologics, Common is a good investment. Please check the relationship between FibroBiologics, Common Cash And Short Term Investments and its Net Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Cash And Short Term Investments vs Net Debt
Cash And Short Term Investments vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroBiologics, Common Cash And Short Term Investments account and Net Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between FibroBiologics, Common's Cash And Short Term Investments and Net Debt is -0.88. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Net Debt in the same time period over historical financial statements of FibroBiologics, Common Stock, assuming nothing else is changed. The correlation between historical values of FibroBiologics, Common's Cash And Short Term Investments and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of FibroBiologics, Common Stock are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Cash And Short Term Investments i.e., FibroBiologics, Common's Cash And Short Term Investments and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.88 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of FibroBiologics, Common balance sheet. This account contains FibroBiologics, Common investments that will expire within one year. These investments include stocks and bonds that can be liquidated by FibroBiologics, Common Stock fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from FibroBiologics, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, FibroBiologics, Common's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 2.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.6M | 4.4M | 8.9M | 9.3M | Research Development | 521K | 1.1M | 2.4M | 1.3M |
FibroBiologics, Common fundamental ratios Correlations
Click cells to compare fundamentals
FibroBiologics, Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.